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Lille and Normandy, France; and Leuven, BelgiumObjectives This study evaluated the impact of nonculprit vessel myocardial perfusion on outcomes of
non–ST-segment elevation acute coronary syndromes (NSTE-ACS) patients.
Background ST-segment elevation myocardial infarction patients have decreased perfusion in areas
remote from the infarct-related vessel. The impact of myocardial hypoperfusion of regions supplied by
nonculprit vessels in NSTE-ACS patients treated with percutaneous coronary intervention (PCI) is
unknown.
Methods The angiographic substudy of the ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial included 6,921 NSTE-ACS patients. Complete 3-vessel assessments of baseline
coronary TIMI (Thrombolysis In Myocardial Infarction) ﬂow grade and myocardial blush grade (MBG)
were performed. We examined the outcomes of PCI-treated patients according to the worst nonculprit
vessel MBG identiﬁed per patient.
Results Among the 3,826 patients treated with PCI, the worst nonculprit MBG was determined
in 3,426 (89.5%) patients, including 375 (10.9%) MBG 0/1 patients, 475 (13.9%) MBG 2 patients, and
2,576 (75.2%) MBG 3 patients. Nonculprit MBG 0/1 was associated with worse baseline clinical
characteristics. Patients with nonculprit MBG 0/1 versus MBG 3 had increased rates of 30-day (3.0%
vs. 0.7%, p < 0.0001) and 1-year (4.4% vs. 1.0%, p < 0.0001) death. Similar results were found among
patients with pre-procedural TIMI ﬂow grade 3 in the culprit vessel, where nonculprit vessel MBG 0/1
(hazard ratio: 2.81 [95% conﬁdence interval: 1.63 to 4.84], p ¼ 0.0002) was the strongest predictor of
1-year mortality.
Conclusions Reduced myocardial perfusion in an area supplied by a nonculprit vessel is associated
with increased short- and long-term mortality rates in NSTE-ACS patients undergoing PCI. Furthermore,
worst nonculprit MBG is able to risk-stratify patients with normal baseline ﬂow of the culprit
vessel. (J Am Coll Cardiol Intv 2014;7:266–75) ª 2014 by the American College of Cardiology
FoundationFrom the *Division of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; yDivision of
Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York; zDivision of
Cardiology, New York University School of Medicine, New York, New York; xDepartment of Medicine, Duke University School of
Medicine, Durham, North Carolina; kGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand;
{Division of Cardiology, Mount Sinai Medical Center, New York, New York; #Department of Cardiology, Hôpital Cardiologique,
Lille, France; **Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; and the yyDepartment of
Abbreviations
and Acronyms
CABG = coronary artery
bypass graft surgery
CAD = coronary artery
disease
MBG = myocardial blush
grade
MI = myocardial infarction
NSTE-ACS = non–ST-segment
elevation acute coronary
syndrome(s)
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial Infarction
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 3 , 2 0 1 4 Lansky et al.
M A R C H 2 0 1 4 : 2 6 6 – 7 5 Nonculprit Vessel MBG Predicts Outcomes in ACS Patients
267Although initial assessments of the coronary vasculature are
focused on evaluating and optimizing epicardial ﬂow, subse-
quent work has revealed that normal epicardial ﬂow does not
necessarily equate to normal tissue perfusion (1,2). Further-
more, changes in epicardial andmyocardial perfusionmay not
be limited to the vessel with the culprit lesion. In ST-segment
elevation myocardial infarctions (STEMIs), alterations in
myocardial perfusion can occur both in areas supplied by and
areas remote from the occluded culprit vessels (3–5) and may
persist even after revascularization of the culprit lesion (6).
These changes in nonculprit vessel myocardial perfusion have
been noted in patients with non ST-segment elevation acute
coronary syndromes (NSTE-ACS) (7).
In the prospective, multicenter ACUITY (Acute Cathe-
terization and Urgent Intervention Triage Strategy) trial,
moderate- to high-risk patients with NSTE-ACS under-
went early invasive management and were subsequently
triaged to treatment with medical management, percuta-
neous coronary intervention (PCI), or coronary artery bypass
graft (CABG) (8,9). We analyzed the impact of abnormal
myocardial perfusion in an area subtended by a nonculprit
vessel on 30-day and 1-year outcomes of PCI patients.
Furthermore, we studied whether abnormal myocardial
perfusion in a nonculprit vessel could further stratify outcomes
of PCI patients with normal culprit vessel epicardial ﬂow.
Methods
The ACUITY study design, major inclusion and exclusion
criteria, endpoints, deﬁnitions, and results have been previ-
ously described in detail (8,9). In summary, 13,819 patients
with moderate- or high-risk NSTE-ACS were prospectively
randomized in an open-label fashion to either heparin
(unfractionated heparin or enoxaparin) plus a glycoprotein
IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa
inhibitor, or bivalirudin alone. Dosing regimens were
described previously (9). All patients underwent angiography
within 72 h of randomization and were subsequently triaged
to PCI, CABG, or medical management at the discretion of
the physician. Primary clinical endpoints were adjudicated
by an independent clinical events committee blinded to
treatment assignment. The major 30-day primary endpoints
were composite ischemic events (death from any cause,
myocardial infarction [MI], or unplanned revascularizationCardiology, University Hospital, Normandy, France. The ACUITY trial was spon-
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col-deﬁned), and net clinical outcomes (composite ischemia
or major bleeding). The major 1-year primary endpoint was
composite ischemic events.
Angiographic analysis. The pre-speciﬁed angiographic sub-
study of the ACUITY trial was composed of the ﬁrst 6,921
consecutive patients enrolled at U.S. centers. Clinical sites
were instructed and trained to acquire protocol-guided
3-vessel diagnostic angiograms prior to intervention. Site
training and prospective protocol for angiography included
administration of intracoronary nitroglycerin, hand or
injector contrast injection, and imaging of each coronary and
its myocardial territory for at least 4 cardiac cycles in a
minimum of 2 orthogonal views using a 5-F or larger cath-
eter. Comprehensive quantitative coronary angiography of
baseline and ﬁnal angiograms was performed by an inde-
pendent angiographic core laboratory. All angiograms were
evaluated by reviewers blinded
to treatment assignment using
validated quantitative methods
(Medis, Leiden, the Netherlands).
Complete baseline 3-vessel and
post-procedural culprit lesion
angiographic data were available
in 3,627 of 3,826 (89.5%) pa-
tients undergoing PCI. Baseline
TIMI (Thrombolysis In Myocar-
dial Infarction) ﬂow grade and
myocardial blush score assessed on
a scale of 0 to 3 was performed at
baseline in all 3 (culprit and non-
culprit) epicardial vessels (1,10).
All angiograms were analyzed by
trained analysts and over-read for
accuracy by a second physician
(A.J.L. or E.C.), who was blin-
ded to clinical outcomes. The
methodology for myocardial blush analysis used (derived
from the original Zwolle description) (1,10) has been pre-
viously described and has been shown to have high intra- and
interobserver reproducibility for prior technicians, and for the
current analysis (C kappa ¼ 0.87 and 0.82 for inter- and
intraobserver variability, respectively). Angiograms were
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2683 following parameters were fulﬁlled: 1) at least 1 view was
present that isolated the myocardial infarct zone; 2) angio-
graphic runs of sufﬁcient duration were present to assess
tissue-level perfusion (usually requiring complete ﬁlling of
the coronary venous system); and 3) complete arterial opa-
ciﬁcation with backﬂow of contrast into the aorta was present
indicating adequate contrast ﬁlling of the epicardial coronary
artery without occlusive catheter wedging.
Myocardial blush was graded in the distribution of the
infarct artery as previously described based on the maximal
densitometric degree of contrast opaciﬁcation: myocardial
blush grade (MBG) 0/1 ¼ no or minimal myocardial
contrast opaciﬁcation; MBG 2 ¼ moderate contrast opaci-
ﬁcation but less than in either an ipsilateral or contralateral
noninfarct artery; and MBG 3 ¼ normal myocardial blush
or contrast opaciﬁcation, comparable with the other coro-
nary arteries. When myocardial blush persisted (“staining”),
MBG 0 was assigned.
The extent of coronary artery disease (CAD) was quan-
tiﬁed by an angiographic surrogate of disease burden (the
total length in millimeters of all lesions with a >30%
diameter stenosis in a major epicardial vessel), and the Duke
jeopardy score estimating the amount of myocardium at risk
on the basis of the particular location of coronary artery
stenosis, in which a higher score corresponds to a greater
area of jeopardized myocardium (11).
Statistical analysis. For this analysis, patients were divided
according to the worst MBGmeasured in a nonculprit vessel.
Culprit vessels were determined by identifying the vessel(s)
treated with PCI in each patient. The lowest MBG in an
untreated vessel in each patient was used to group patients.
Baseline features and outcomes were compared by worst
MBG. Categorical variables are presented as percentages and
were compared by either the chi-square or Fisher exact test.
Continuous variables are presented as mean  SD or as me-
dian (interquartile range) andwere compared by the analysis of
variance/Kruskal-Wallis test. Thirty-day and 1-year out-
comes are displayed with Kaplan-Meier methodology and
compared using the log-rank test. Multivariable analysis was
performed using a Cox regression analysis with entry criteria
of p¼ 0.10 and stay criteria of p¼ 0.10. For the evaluation of
predictors of 1-year death/MI, candidate baseline variables
included age, sex, diabetes, hypertension, hyperlipidemia,
previous MI, prior percutaneous transluminal
coronary angioplasty, prior CABG, renal insufﬁciency, cur-
rent smoking, baseline cardiac biomarker elevation or ST-
segment deviation, 3-vessel disease, chronic total occlusion in
the vessel with the worst blush score, and nonculprit MBG 0/
1 (vs. 2/3). To evaluate the predictors of 1-year mortality,
candidate predictors included age, diabetes, hypertension,
current smoking, 3-vessel disease, chronic total occlusion in
the vessel with the worst blush score, and nonculprit MBG 0/
1 (vs. 2/3). All statistical analyses were performed using SAS
(version 8.2, SAS Institute Inc., Cary, North Carolina).Results
Baseline characteristics according to the worst nonculprit
vessel MBG. Among the 3,826 patients in the angiographic
substudy triaged to PCI, 3,426 patients (89.5%) had
analyzable nonculprit MBG including MBG 0/1 in 375
(10.9%) patients, MBG 2 in 475 (13.9%) patients, andMBG
3 in 2,576 (75.2%) patients. Patients with nonculprit MBG
0/1 were older than patients with nonculprit MBG 3 and had
higher rates of diabetes, hypertension, hyperlipidemia, prior
MI, and prior percutaneous transluminal coronary angio-
plasty than the other groups (Table 1). Randomization to
antithrombotic medications was well matched between the
groups. Patients with nonculprit vessel MBG 0/1 had less
culprit lesion drug-eluting stent use (75.7% vs. 84.5%,
p< 0.0001) and more bare-metal stent use (19.7% vs. 13.7%,
p ¼ 0.002) compared with patients with normal nonculprit
myocardial perfusion.
Atherosclerotic disease burden increased with decreasing
MBG in the nonculprit vessels. The number of lesions and
rate of 3-vessel disease increased with worsening nonculprit
MBG. Nonculprit MBG 0/1 was associated with higher-
risk culprit lesion characteristics, such as longer lesions,
more thrombus, and moderate/severe calciﬁcation, than
other patients. Rates of normal baseline and post-procedural
culprit vessel TIMI ﬂow decreased with worsening non-
culprit MBG. Patients with nonculprit vessel MBG 0/1
were less likely to have normal culprit vessel MBG at
baseline and post-procedure than were patients with normal
nonculprit vessel MBG (Table 2).
Outcomes according to the worst nonculprit vessel MBG.
The 30-day and 1-year composite ischemia (30-day 13.9%
vs. 9.4%, p ¼ 0.006; 1-year 27.6% vs. 19.5%, p ¼ 0.0007),
death/MI (30-day 11.5% vs. 7.7%, p ¼ 0.01; 1-year 18.0%
vs. 11.4%, p ¼ 0.0002) (Fig. 1A), and mortality rates
(30-day 3.0% vs. 0.7%, p < 0.0001; 1-year 6.9% vs. 2.3%,
p < 0.0001) (Fig. 1B) were higher in patients with non-
culprit MBG 0/1 than in patients with MBG 3. Further-
more, 1-year MI (13.5% vs. 9.9%, p ¼ 0.03) and cardiac
mortality rates (4.4% vs. 1.0%, p < 0.0001) were higher in
nonculprit MBG 0/1 versus MBG 3 patients.
Impact of impaired nonculprit MBG among patients with
normal culprit vessel ﬂow. In the angiographic subgroup,
2,436 (63.7%) PCI patients with analyzable MBG had
normal culprit vessel TIMI ﬂow at baseline, which included
MBG 0/1 in 244 (10.0%) patients, MBG 2 in 316 (13.0%)
patients, and MBG 3 in 1,876 (77.0%) patients. Patient
demographics in Table 1 demonstrate that among patients
with normal baseline culprit TIMI ﬂow, the presence of
nonculprit vessel MBG 0/1 identiﬁes patients that were older
with more diabetes, hypertension, prior percutaneous trans-
luminal coronary angioplasty, and prior MI than other
patients. In addition, MBG 0/1 patients had more hyper-
lipidemia and were less likely to receive a culprit lesion
Table 1. Baseline Characteristics According to Worst MBG in a Nonculprit Vessel
Baseline MBG Flow p Value
0/1 2 3 All Groups 0/1 vs. 2 0/1 vs. 3 2 vs. 3
Overall population
Age at randomization, yrs 63.00 (54.00–73.00) 61.00 (53.00–71.00) 61.00 (52.00–70.00) 0.002 0.07 0.0007 0.21
Male 76.3 (286/375) 73.9 (351/475) 67.0 (1,727/2,576) <0.0001 0.43 0.0003 0.003
Diabetes 43.9 (163/371) 30.9 (145/470) 29.8 (765/2,568) <0.0001 <0.0001 <0.0001 0.64
Insulin diabetes 12.4 (46/371) 9.6 (45/470) 8.3 (214/2,568) 0.03 0.19 0.01 0.38
Hypertension 79.6 (297/373) 66.4 (314/473) 68.8 (1,765/2,567) <0.0001 <0.0001 <0.0001 0.31
Hyperlipidemia 69.8 (259/371) 63.0 (294/467) 59.9 (1,524/2,544) 0.0009 0.04 0.0003 0.22
Current smoker 27.3 (102/374) 28.8 (137/475) 33.6 (861/2,562) 0.01 0.61 0.01 0.04
Previous myocardial infarction 53.0 (193/364) 34.4 (160/465) 32.2 (809/2,509) <0.0001 <0.0001 <0.0001 0.36
Previous percutaneous transluminal
coronary angioplasty
57.4 (214/373) 47.6 (225/473) 46.6 (1,196/2,564) 0.0005 0.005 0.0001 0.71
Renal insufﬁciency 20.2 (69/342) 17.1 (77/449) 16.5 (399/2,411) 0.25 0.28 0.09 0.75
White blood cell count 8.20 (6.66–10.20) 7.75 (6.30–9.50) 8.00 (6.40–9.70) 0.11 0.04 0.11 0.25
C-reactive protein 0.70 (0.31–2.26) 0.60 (0.30–1.81) 0.70 (0.32–2.10) 0.42 0.23 0.58 0.27
Baseline cardiac biomarker elevation 62.1 (218/351) 55.9 (247/442) 56.9 (1,367/2,403) 0.15 0.08 0.06 0.70
Baseline troponin elevation 60.4 (200/331) 56.8 (233/410) 57.0 (1,274/2,235) 0.49 0.32 0.24 0.95
ST-segment deviation 1 mm 31.2 (117/375) 27.8 (132/475) 24.8 (638/2,576) 0.02 0.28 0.008 0.16
Baseline cardiac biomarker elevation
or ST-segment deviation
72.6 (260/358) 67.1 (304/453) 65.7 (1,608/2,446) 0.04 0.09 0.01 0.57
Patients with baseline culprit vessel
TIMI ﬂow grade 3
Age at randomization, yrs 63.00 (55.00–74.00) 60.00 (52.00–70.50) 61.00 (53.00–70.00) 0.02 0.02 0.006 0.94
Male 75.8 (185/244) 74.4 (235/316) 65.0 (1,219/1,876) <0.0001 0.69 0.0008 0.001
Diabetes 44.2 (107/242) 33.7 (105/312) 30.6 (571/1,868) <0.0001 0.01 <0.0001 0.28
Insulin diabetes 12.8 (31/242) 9.9 (31/312) 8.2 (154/1,868) 0.05 0.29 0.02 0.32
Hypertension 81.1 (198/244) 71.7 (225/314) 70.8 (1,322/1,867) 0.003 0.009 0.0007 0.76
Hyperlipidemia 71.2 (173/243) 64.2 (199/310) 62.2 (1,153/1,853) 0.02 0.08 0.006 0.51
Current smoker 25.9 (63/243) 27.8 (88/316) 32.9 (613/1,866) 0.03 0.61 0.03 0.08
Previous myocardial infarction 54.2 (129/238) 34.3 (106/309) 32.8 (598/1,823) <0.0001 <0.0001 <0.0001 0.60
Previous percutaneous transluminal
coronary angioplasty
61.9 (151/244) 53.0 (167/315) 51.5 (961/1,865) 0.010 0.04 0.002 0.63
Renal insufﬁciency 20.9 (46/220) 16.9 (51/301) 17.8 (313/1,757) 0.47 0.25 0.26 0.71
White blood cell count 7.90 (6.20–9.90) 7.50 (6.10–9.40) 7.80 (6.30–9.40) 0.37 0.25 0.77 0.18
C-reactive protein 0.70 (0.30–2.00) 0.50 (0.30–1.40) 0.68 (0.30–2.00) 0.23 0.19 0.84 0.10
Baseline cardiac biomarker elevation 55.1 (125/227) 50.8 (150/295) 48.8 (845/1,732) 0.19 0.34 0.08 0.51
Baseline troponin elevation 52.8 (112/212) 52.0 (140/269) 48.9 (780/1,594) 0.41 0.86 0.29 0.35
ST-segment deviation 1 mm 25.8 (63/244) 26.3 (83/316) 22.4 (420/1,876) 0.19 0.91 0.23 0.13
Baseline cardiac biomarker elevation
or ST-segment deviation
65.9 (153/232) 62.9 (190/302) 58.7 (1,038/1,769) 0.06 0.47 0.03 0.17
Values are median (interquartile range), or % (n/N).
MBG ¼ myocardial blush grade; TIMI ¼ Thrombolysis In Myocardial Infarction.
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269drug-eluting stent (79.9% vs. 86.5%, p ¼ 0.006) than were
MBG 3 patients.
Patients with baseline culprit lesion TIMI ﬂow grade
3 but reduced nonculprit MBG had greater atherosclerotic
disease burden with more lesions per patient, 3-vessel dis-
ease, and higher Duke jeopardy scores. Patients with non-
culprit MBG 0/1 had longer culprit lesion length and more
lesions with calciﬁcation than other patients did (Table 3).
Despite culprit lesion TIMI ﬂow grade 3 at baseline,
patients with baseline nonculprit vessel MBG 0/1 hadhigher rates of composite ischemia (30-day: 14.4% vs. 8.2%
vs. 9.0%, p ¼ 0.02; 1-year: 26.7% vs. 18.0% vs. 20.6%,
p ¼ 0.02), death/MI (30-day: 12.3% vs. 5.4% vs. 7.5%,
p ¼ 0.009; 1-year: 19.3% vs. 10.0% vs. 11.6%, p ¼ 0.001)
(Fig. 2A), overall death (30-day: 3.3% vs. 0.3% vs. 0.5%,
p < 0.0001; 1-year: 7.6% vs. 2.0% vs. 2.3%, p < 0.0001)
(Fig. 2B), and cardiac death (30-day: 3.3% vs. 0.3% vs.
0.4%, p < 0.0001; 1-year: 4.6% vs. 1.6% vs. 1.0%,
p < 0.0001) at 30 days and 1 year than did patients with
either nonculprit MBG 2 or 3.
Table 2. Angiographic Characteristics According to Worst Nonculprit MBG in the Overall PCI Population
Baseline MBG Flow p Value
0/1 2 3 All Groups 0/1 vs. 2 0/1 vs. 3 2 vs. 3
Overall population
Burden of disease
Lesions per patient, n 5.93  2.71 (374) 4.68  2.86 (475) 3.94  2.34 (2,575) <0.0001 <0.0001 <0.0001 <0.0001
Extent of disease
per patient, mm
34.27 (21.10–52.00) 35.54 (20.00–57.00) 32.50 (19.33–51.00) 0.04 0.73 0.15 0.03
Diseased vessels, n
0 0.3 (1/375) 0.2 (1/475) 0.2 (5/2,576) 0.96 0.87 0.77 0.94
1 4.5 (17/375) 15.8 (75/475) 22.2 (572/2,576) <0.0001 <0.0001 <0.0001 0.002
2 20.5 (77/375) 32.0 (152/475) 36.6 (943/2,576) <0.0001 0.0002 <0.0001 0.05
3 74.7 (280/375) 52.0 (247/475) 41.0 (1,056/2,576) <0.0001 <0.0001 <0.0001 <0.0001
Duke jeopardy score 4.85  2.48 (352) 2.76  2.50 (469) 2.31  2.13 (2,502) <0.0001 <0.0001 <0.0001 <0.0001
Baseline culprit lesion characteristics
Lesion location
LAD 28.7 (143/499) 38.4 (228/593) 34.4% (1,167/3,392) 0.003 0.0007 0.011 0.06
RCA 34.1 (170/499) 29.7 (176/593) 35.8 (1,214/3,392) 0.01 0.12 0.45 0.004
LCX 37.3 (186/499) 31.9 (189/593) 29.8 (1,011/3,392) 0.003 0.06 0.0007 0.31
Lesion length, mm 17.72  12.60 (438) 15.71  10.97 (587) 15.58  9.83 (3,320) 0.0002 0.002 <0.0001 0.77
Thrombus 22.8 (114/499) 16.5 (98/593) 14.5 (492/3,390) <0.0001 0.009 <0.0001 0.20
Calciﬁcation: moderate/severe 31.3 (151/483) 23.2 (134/578) 23.9 (796/3,332) 0.001 0.003 0.0005 0.71
TIMI ﬂow grade
0/1 37.7 (187/496) 9.9 (59/593) 10.4 (351/3,387) <0.0001 <0.0001 <0.0001 0.76
2 9.1 (45/496) 14.7 (87/593) 8.1 (275/3,387) <0.0001 0.005 0.47 <0.0001
3 53.2 (264/496) 75.4 (447/593) 81.5 (2,761/3,387) <0.0001 <0.0001 <0.0001 0.0005
Blush
0/1 50.1 (227/453) 14.3 (82/572) 12.0 (391/3,265) <0.0001 <0.0001 <0.0001 0.11
2 11.9 (54/453) 65.6 (375/572) 8.3 (272/3,265) <0.0001 <0.0001 0.01 <0.0001
3 39.4 (177/449) 21.5 (121/564) 81.2 (2,628/3,235) <0.0001 <0.0001 <0.0001 <0.0001
QCA
RVD, mm 2.82  0.60 (439) 2.76  0.54 (563) 2.75  0.56 (3,326) 0.03 0.10 0.007 0.50
MLD, mm 0.71  0.49 (439) 0.71  0.49 (563) 0.73  0.46 (3,326) 0.75 0.99 0.59 0.55
DS% 74.78  15.97 (439) 74.30  16.25 (563) 73.48  15.80 (3,326) 0.18 0.64 0.11 0.26
Post-procedure culprit lesion characteristics
TIMI ﬂow grade
0/1 6.4 (23/361) 1.7 (9/540) 0.8 (29/3,462) <0.0001 0.0002 <0.0001 0.06
2 3.9 (14/361) 2.4% (13/540) 1.2% (43/3462) 0.0002 0.20 <0.0001 0.03
3 89.8% (324/361) 95.9 (518/540) 97.9 (3,390/3,462) <0.0001 0.0002 <0.0001 0.004
Blush
0/1 29.4 (94/320) 16.9 (88/520) 11.9 (398/3,343) <0.0001 <0.0001 <0.0001 0.001
2 16.6 (53/320) 60.8 (316/520) 8.2 (275/3,343) <0.0001 <0.0001 <0.0001 <0.0001
3 75.9 (227/299) 39.5 (190/481) 95.2 (3,085/3,242) <0.0001 <0.0001 <0.0001 <0.0001
QCA
RVD, mm 2.85  0.59 (429) 2.80  0.52 (558) 2.78  0.56 (3,307) 0.05 0.17 0.01 0.41
Lesion MLD, mm 2.33  0.62 (429) 2.31  0.55 (558) 2.31  0.56 (3,306) 0.77 0.63 0.47 0.90
DS% 18.37  13.25 (429) 17.32  13.25 (558) 17.12  11.34 (3,306) 0.12 0.17 0.04 0.70
Acute gain lesion, mm 1.61  0.65 (429) 1.60  0.62 (558) 1.58  0.61 (3,305) 0.59 0.84 0.40 0.50
Acute gain stent, mm 1.95  0.59 (381) 1.96  0.55 (504) 1.94  0.56 (2,996) 0.84 0.93 0.73 0.60
Values are mean  SD (n), median (interquartile range), or % (n/N).
DS% ¼ percentage of diameter stenosis; LAD ¼ left anterior descending; LCX ¼ left circumﬂex; MLD ¼minimal lumen diameter; PCI ¼ percutaneous coronary intervention; QCA ¼ quantitative coronary
angiography; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; other abbreviations as in Table 1.
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Figure 1. Kaplan-Meier Time-to-Event Curves in Overall PCI Population
According to Worst Nonculprit MBG
(A) Kaplan-Meier time-to-event curve of 1-year death/myocardial infarction.
(B) Kaplan-Meier time-to-event curve of 1-year death. MBG ¼ myocardial
blush grade; PCI ¼ percutaneous coronary intervention.
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271Nonculprit MBG 0/1, prior MI, renal insufﬁciency, base-
line cardiac biomarker elevation or ST-segment deviations,
and 3-vessel disease were independent predictors of death/MI
at 1 year in patients with culprit TIMI ﬂow grade 3 (Table 4).
Furthermore, nonculprit MBG 0/1, age, and diabetes were
independent predictors of 1-year mortality (Table 4) in
patients with normal culprit vessel ﬂow.
Discussion
This analysis demonstrates that among moderate- and high-
risk NSTE-ACS patients, abnormal myocardial perfusion in
regions not supplied by the culprit vessel is common,
occurring in one-quarter of patients, and adversely affects
short- and long-term clinical outcomes. Compared with
normal nonculprit vessel ﬂow characteristics, MBG 0/1 in a
nonculprit vessel is associated with more comorbid disease,greater atherosclerotic disease burden, and increased 30-day
and 1-year mortality. Furthermore, abnormal nonculprit
myocardial perfusion was found to be an independent pre-
dictor of increased mortality among patients with normal
baseline culprit vessel epicardial ﬂow.
Although the focus of coronary revascularization has been
on restoring normal epicardial ﬂow in the culprit vessel, this
does not necessarily equate with normal myocardial perfu-
sion. After primary angioplasty for STEMI, only a minority
of patients achieves normal myocardial tissue perfusion
(1,2), and decreased myocardial perfusion is associated with
signiﬁcantly higher rates of short- and long-term mortality
(1,2,12). Furthermore, post-intervention infarct artery
MBG can be used to stratify patients with TIMI ﬂow grade
3 after reperfusion into different risk categories (13,14).
Epicardial and myocardial perfusion abnormalities in regions
subtended by the noninfarct-related arteries in patients with
STEMI also carry prognostic signiﬁcance (3–5,7,15,16).
Measured angiographically in acute MI patients, epicardial
ﬂow in nonculprit vessels may be slowed by as much as 50%
compared with normal ﬂow (3). Furthermore, 40% of acute
MI patients have evidence of abnormal myocardial perfu-
sion in nonculprit vessels (4). These abnormalities have
also been shown in studies using fractional ﬂow reserve,
Doppler echocardiography, and positron emission tomog-
raphy (6,17–22). Whereas prior studies have focused on
STEMI patients, our analysis of the ACUITY trial expands
these observations by demonstrating that a substantial subset
of patients undergoing PCI for NSTE-ACS have abnormal
myocardial nonculprit vessel perfusion (24.8% of patients) as
measured by MBG. Furthermore, among patients with
normal baseline TIMI ﬂow grade in the culprit vessel, 23.0%
of patients had abnormal MBG in a nonintervened artery.
Whereas decreased perfusion in the culprit vessel is often
attributed to plaque disruption, thrombus, and distal
embolization (23–25), this cannot explain perfusion defects
in the nonintervened vessels. Instead, impaired coronary
ﬂow found in nonintervened vessels may be secondary to
diffuse inﬂammation. In addition to the local inﬂammatory
processes that lead to vulnerable plaque development and
rupture (26–28), there is also widespread activation of in-
ﬂammatory pathways in the coronary vasculature of patients
with unstable angina (29–31). Thus, despite normal angio-
graphic appearances, there may be increased inﬂammation in
nonculprit vessels (29). In addition to inﬂammatory cyto-
kines, there are also increased vasoconstrictor mediators in
the coronary circulation in ACS patients that can further
augment myocardial tissue perfusion abnormalities (32,33).
The increase in coronary inﬂammatory and vasoconstrictor
cytokines may account for the abnormal myocardial perfu-
sion found in nonculprit vessels in our study. Furthermore,
the degree of disease in the culprit vessel may modulate the
severity of cytokine release and affect the amount of ﬂow or
perfusion through the nonculprit vessels. Consistent with
Table 3. Angiographic Characteristics According to Worst Nonculprit MBG in PCI Patients With Baseline Culprit Vessel TIMI Flow Grade 3
Baseline MBG Flow p Value
0/1 2 3 All Groups 0/1 vs. 2 0/1 vs. 3 2 vs. 3
Burden of disease
Lesions per patient, n 5.91  2.68 (244) 4.58  2.87 (316) 3.91  2.32 (1,876) <0.0001 <0.0001 <0.0001 <0.0001
Extent of disease per patient, mm
diseased vessels, n
35.40 (22.15–52.00) 35.00 (19.72–55.00) 33.26 (20.00–51.39) 0.33 0.54 0.17 0.46
0 0.0 (0/244) 0.0 (0/316) 0.1 (1/1,876) 0.86 d 0.72 0.68
1 4.1 (10/244) 16.5 (52/316) 22.7 (426/1,876) <0.0001 <0.0001 <0.0001 0.01
2 18.9 (46/244) 32.6 (103/316) 36.6 (686/1,876) <0.0001 0.0003 <0.0001 0.17
3 77.0 (188/244) 50.9 (161/316) 40.7 (763/1,876) <0.0001 <0.0001 <0.0001 0.0006
Duke jeopardy score 4.63  2.49 (227) 2.39  2.31 (312) 2.07  2.09 (1,823) <0.0001 <0.0001 <0.0001 0.02
Baseline culprit lesion characteristics
Lesion location
LAD 31.7 (82/259) 36.9 (155/420) 34.9 (909/2,604) 0.38 0.16 0.29 0.43
RCA 29.3 (76/259) 29.0 (122/420) 35.7 (930/2,604) 0.006 0.93 0.04 0.008
LCX 39.0 (101/259) 34.0 (143/420) 29.4 (765/2,604) 0.002 0.19 0.001 0.05
Lesion length, mm 16.55  11.74 (259) 14.81  9.57 (420) 15.14  9.67 (2,601) 0.06 0.03 0.03 0.53
Thrombus 9.3 (24/259) 7.1 (30/420) 8.0 (207/2,603) 0.61 0.32 0.46 0.57
Calciﬁcation: moderate/severe 30.4 (75/247) 23.4 (95/406) 21.9 (561/2,558) 0.01 0.049 0.003 0.51
Blush
0/1 11.7 (26/223) 4.0 (16/403) 1.0 (26/2,516) <0.0001 0.0002 <0.0001 <0.0001
2 17.9 (40/223) 68.2 (275/403) 7.2 (180/2,516) <0.0001 <0.0001 <0.0001 <0.0001
3 71.5 (158/221) 27.9 (111/398) 92.3 (2,303/2,494) <0.0001 <0.0001 <0.0001 <0.0001
QCA
RVD, mm 2.81  0.56 (303) 2.74  0.50 (391) 2.74  0.55 (2,496) 0.10 0.11 0.03 0.85
MLD, mm 0.83  0.44 (303) 0.81  0.43 (391) 0.83  0.42 (2,496) 0.74 0.59 0.99 0.44
DS% 70.68  13.72 (303) 70.71  14.06 (391) 69.72  13.81 (2,496) 0.26 0.98 0.25 0.19
Post-procedure culprit lesion characteristics
TIMI ﬂow grade
0/1 0.8 (2/245) 0.0 (0/387) 0.1 (3/2,598) 0.02 0.08 0.01 0.50
2 0.8 (2/245) 0.3 (1/387) 0.3 (8/2,598) 0.41 0.32 0.20 0.87
3 98.4 (241/245) 99.7 (386/387) 99.6 (2,587/2,598) 0.03 0.06 0.01 0.63
Blush
0/1 6.6 (14/211) 4.9 (18/369) 1.0 (26/2,521) <0.0001 0.37 <0.0001 <0.0001
2 19.0 (40/211) 64.8 (239/369) 7.2 (181/2,521) <0.0001 <0.0001 <0.0001 <0.0001
3 84.7 (172/203) 42.4 (147/347) 97.0 (2,380/2,454) <0.0001 <0.0001 <0.0001 <0.0001
QCA
RVD, mm 2.86  0.57 (299) 2.78  0.49 (389) 2.78  0.55 (2,481) 0.07 0.06 0.02 0.99
Lesion MLD, mm 2.36  0.58 (299) 2.32  0.50 (389) 2.32  0.55 (2,480) 0.41 0.31 0.18 0.95
DS% 17.31  10.87 (299) 16.35  10.44 (389) 16.61  10.10 (2,480) 0.44 0.22 0.26 0.63
Acute gain lesion, mm 1.54  0.59 (299) 1.51  0.54 (389) 1.49  0.57 (2,480) 0.40 0.60 0.21 0.51
Acute gain stent, mm 1.90  0.52 (263) 1.85  0.48 (353) 1.85  0.52 (2,246) 0.35 0.20 0.17 0.81
Values are mean  SD (n), median (interquartile range), or % (n/N).
Abbreviations as in Tables 1 and 2.
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was slower in patients with worse culprit vessel ﬂow (3,34),
we observed that patients with MBG 0/1 in a nonintervened
vessel were less likely to have TIMI ﬂow grade 3 or MBG
3 in the culprit vessel.
Patients with nonculprit MBG 0/1 had higher composite
ischemia and mortality rates than did patients with normalnonculprit vessel ﬂow and perfusion at both 30-day and
1-year follow-up. Moreover, nonculprit MBG 0/1 patients
had signiﬁcantly worse outcomes than did patients with
MBG 2 or 3, whereas patients with MBG 2 and 3 had
similar outcomes, suggesting that the critical distinction is
between the presence of an open versus closed microcircu-
lation. Thus, the worst MBG in a nonculprit vessel provides
Table 4. Multivariable Analysis of Death/MI and Death in Patients
With TIMI Flow Grade 3 in the Culprit Vessel
HR (95% CI) p Value
Death/MI
Nonculprit MBG 0/1 vs. 2/3 1.58 (1.12–2.21) 0.009
Prior MI 1.41 (1.09–1.65) 0.01
Renal insufﬁciency 2.44 (1.88–3.18) <0.0001
Baseline cardiac biomarker elevation
or ST-segment deviation
1.57 (1.20–2.07) 0.001
3-vessel disease 1.45 (1.12–1.88) 0.006
Death
Nonculprit MBG 0/1 vs. 2/3 2.41 (1.37–4.22) 0.002
Age, 10-year increments 2.05 (1.62–2.59) <0.0001
Diabetes 2.22 (1.37–3.62) 0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; other abbreviations as
in Table 1.
Figure 2. Kaplan-Meier Time-to-Event Curves in Patients With Culprit
TIMI Flow Grade 3 According to Worst Nonculprit MBG
(A) Kaplan-Meier time-to-event curve of 1-year death/myocardial infarction.
(B) Kaplan-Meier time-to-event curve of 1-year death. MBG ¼ myocardial
blush grade; TIMI ¼ Thrombolysis In Myocardial Infarction.
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273important outcome stratiﬁcation information even among
patients with normal baseline culprit epicardial blood ﬂow.
The poor outcomes of patients with poor myocardial
perfusion may be secondary to left ventricular remodeling
and decreased left ventricular function over time. Previous
studies have demonstrated that poor myocardial perfusion in
the culprit artery leads to long-term left ventricular dilation
and decreased left ventricular function even after normal-
izing epicardial ﬂow (13,22,35,36). This process may be
ampliﬁed and accelerated when additional territories in
nonculprit vessels have poor perfusion.
In this study, patients with nonculprit vessel MBG 0/1
had higher rates of comorbid conditions including older age,
hypertension, diabetes, hyperlipidemia, and more extensive
CAD. These factors have been associated with decreased
coronary blood ﬂow reserve even in the absence of CAD
(37–39) and are associated with worse cardiac outcomes
(40–44). Furthermore, approximately 44% of patients with
MBG 0/1 in a nonculprit vessel had diabetes, which is
associated with diffuse CAD resulting in difﬁcult-to-treat
CAD and worse outcomes (32,33,35). Nonetheless, the
absence of myocardial blush remained an independent risk
factor for increased mortality and death/MI at 1 year among
patients with normal culprit TIMI ﬂow grade after multi-
variate analysis.
Study limitations. This is a post-hoc analysis and must
be considered hypothesis-generating. Although the study
contained a large angiographic subset, this study was not
powered to detect differences in outcomes based on angio-
graphic characteristics. The results of this study can only be
applied to patients who met the inclusion and exclusion
criteria of the overall trial. Myocardial tissue perfusion was
measured using MBG in this study, and conclusions cannot
be drawn regarding the prognostic abilities of other modal-
ities of measuring myocardial perfusion. It is possible that
multiple culprits may have affected the results of this study.
The culprit lesion and vessel in this analysis were driven
clinically by the investigator on the basis of the integration of
clinical presentation, electrocardiographic ﬁndings, and
angiographic lesions characteristics such as severity and
thrombus presence. If multiple lesions were treated with
PCI, those were excluded from nonculprit analysis. This trial
did not routinely follow left ventricular function in the study
participants; thus, the relationship between nonculprit MBG
and left ventricular remodeling and function could not be
described in this analysis.
Conclusions
Our analysis revealed that up to one-quarter of moderate-
to high-risk NSTE-ACS patients undergoing PCI have
abnormal microvascular perfusion of the nonculprit vessels.
A reduction in nonculprit MBG predicts worse ischemic
outcomes than for patients with normal nonculprit perfusion.
Lansky et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 3 , 2 0 1 4
Nonculprit Vessel MBG Predicts Outcomes in ACS Patients M A R C H 2 0 1 4 : 2 6 6 – 7 5
274Even among patients with normal culprit vessel ﬂow,
reduced nonculprit vessel ﬂow is common and associated
with a higher mortality.
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